Lisheng Pharmaceuticals announced that the company recently received the “Drug Registration Certificate” for sacubatl valsartan tablets issued by the State Drug Administration, and the drug has passed the marketing license application. The drug is a chemical. Indications include adult patients with chronic heart failure and primary hypertension with reduced ejection fraction. Approved production according to the 4 categories of chemicals is considered to have passed the consistency evaluation, which will enrich the company's circulatory system drug product line. There is uncertainty about the subsequent sales of this drug, so investors are kindly requested to pay attention to investment risks.

Lisheng Pharmaceuticals announced that the company recently received the “Drug Registration Certificate” for sacubatl valsartan tablets issued by the State Drug Administration, and the drug has passed the marketing license application. The drug is a chemical. Indications include adult patients with chronic heart failure and primary hypertension with reduced ejection fraction. Approved production according to the 4 categories of chemicals is considered to have passed the consistency evaluation, which will enrich the company's circulatory system drug product line. There is uncertainty about the subsequent sales of this drug, so investors are kindly requested to pay attention to investment risks.